Covalent Drug Discovery Summit on December 12-14, 2023 in Boston, United States

The field of targeted covalent therapeutics is seeing a surge of activity, with both new and established companies investing heavily in the space. The inaugural Covalent Drug Discovery Summit has been built alongside industry experts to provide a dedicated forum to tackle associated challenges and advance covalent therapeutics; previously only afforded a small feature in larger 'small molecule' conferences.

As the very first meeting solely focused on covalent therapeutics, the 18+ speaker faculty boasts leaders from large pharma, new biotech and academia. This is the summit to meet 80+ covalency experts gathering to solve target selectivity, hit screening, lead optimization, and covalent warhead design to carve out covalency's niche for targeting the "undruggable" proteome.

URLs:
Brochure: https://go.evvnt.com/1900494-0?pid=10008

Tickets: https://go.evvnt.com/1900494-2?pid=10008

Time: 7:30 AM - 5:00 PM

Prices:

Drug Developer Pricing - Conference Only: USD 2999.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,

Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,

Academic Pricing - Conference Only: USD 2599.00,

Academic Pricing - Conference + 1 Workshop: USD 3148.00,

Academic Pricing - Conference + 2 Workshops: USD 3697.00,

Solution Provider Pricing - Conference Only: USD 3799.00,

Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,

Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00

Speakers: Alun Bermingham, Senior Vice President and Head of Platform, Totus Medicines, Anthony Rullo, Associate Professor of Medicine and Chemical Biology, McMaster University, Brent Martin, Vice President - Head of Chemical Biology, Scorpion Therapeutics, Brian Lanman, Director of Research, Amgen, David Weinstein, Vice President and Head of Chemistry, Vividion Therapeutics, Eranthie Weerapana, Professor of Chemistry, Boston College, Herman Lik Hang Yuen, Associate Director, DEL Informatics and Cheminformatics, Nurix, Ivan Cornella, Chief Scientific Officer, Covant Therapeutics, Jeff McKenna, Director of Hit Generation and Covalent Drug Discovery, Novartis AG, Jeffrey Martin, Principal Scientist, Biogen, John Knox, Vice President - Structural Chemistry and Discovery Sciences, Revolution Medicines Inc., Laura D’Agostino, Vice President of Chemistry, Dunad Therapeutics, Lei Wang, Professor, University of Califorina, San Francisco, Neil Dhawan, Chief Executive Officer, Totus Medicines, Ping Cao, Chief Executive Officer, Bridgene Biosciences, Ruben Tommasi, Chief Scientific Officer, Dunad Therapeutics, Simona Cotesta, Director of Global Discovery Chemistry, Novartis, Stephen Baker, Head Of Chemistry Reactive, Biosciences, Thorsten Kirschberg, Executive Vice President of Chemistry, Biomea Fusion, Tinghu Zhang, Senior Scientist, (Nathanael Gray’s Lab) Stanford University, Ziyang Zhang, Professor of Chemistry and Chemical Biology, University of California Berkeley